UCLA study: High-dose radiotherapy + chemo effective in treating NSCLC

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A study led by researchers from the UCLA Health Jonsson Comprehensive Cancer Center showed that using high doses of radiation while integrating an ablative radiotherapy technique called stereotactic ablative radiotherapy concurrently with chemotherapy is safe and effective in treating people with locally advanced non-small cell lung cancer that is not suitable for surgery.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Traditional pathological features used to classify aggressive prostate cancer—such as high-grade disease, cancer extending outside the prostate and cancer involving the seminal vesicles—after surgery do not predict who will benefit more from adding hormone therapy to postoperative radiation, according to a study led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center. 
Cristina Puig-Saus, an associate professor of microbiology, immunology and molecular genetics and surgical oncology at the David Geffen School of Medicine at UCLA and an investigator at the UCLA Health Jonsson Comprehensive Cancer Center, and her research team have received a five-year, $3.9 million grant from NCI to develop drug-based strategies that could enhance cancer immunotherapy for patients with melanoma and potentially other types of cancer. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login